ADMA Biologics, Inc. 8-K Report: Key Developments on January 13, 2025
Based on the provided section of the financial report, here are the key insights and information extracted:
- Entity Information:
- Company Name: ADMA Biologics, Inc.
- State of Incorporation: Delaware (DE)
- CIK: 0001368514
- SEC File Number: 001-36728
- Employer Identification Number (EIN): 56-2590442
- Address: 465 State Route 17, Ramsey, NJ 07446
- Contact Number: 201-478-5552
- Filing Details:
- Filing Type: 8-K (Current Report)
- Filing Date: January 13, 2025
- Stock Information:
- Common Stock Symbol: ADMA
- Exchange: NASDAQ
- Period Information:
- Reporting Period: The report covers a single day, specifically January 13, 2025.
- XBRL Metadata:
- The filing is structured in XBRL (eXtensible Business Reporting Language), which allows for standardized electronic reporting of financial data.
Insights:
- This report appears to be an 8-K filing, which is typically used to notify investors of significant events that may affect the company's financial position or operations.
- The single-day reporting period suggests that the content of the 8-K may pertain to a specific event or announcement occurring on that date.
- The company is publicly traded on NASDAQ, indicating it is subject to SEC regulations and reporting requirements.
This information is crucial for investors, analysts, and stakeholders to understand recent developments relating to ADMA Biologics, Inc.